|Mauna Kea Technologies SA -- France Stock|| |
EUR 3.14 0.11 3.38%
President for North America
Mr. Guillaume Bailliard is the President for North America of Mauna Kea Technologies SA. He began his career as a design engineer for Genzyme Surgical and then joined GE Healthcare where he held various sales and management positions including managing the Americas XRay Sales operations. Following that experience he joined Naviscan where he played a role in launching a breast cancer imaging system in a developing market serving most recently as Executive Vice President of Global Sales and Marketing. He holds an Executive MBA from Emory University in Atlanta Georgia and a Bachelor of Mechanical Engineering from Georgia Tech.
33 1 48 24 03 45 http://www.maunakeatech.com
The company has return on total asset (ROA)
of (35.99) %
which means that it has lost $35.99 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (123.6) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 6.82 M in total debt with debt to equity ratio (D/E) of 83.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Mauna Kea Technologies SA has Current Ratio of 3.35 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Mauna Kea Technologies SA, a medical device company, develops and sells endomicroscopy and optical biopsy for the diagnosis and treatment of cancer and other diseases. The company was founded in 2000 and is headquartered in Paris, France. Mauna Kea operates under Medical Appliances Equipment classification in France and traded on Paris Stock Exchange exchange. It employs 81 people.Mauna Kea Technologies SA (MKEA) is traded on Paris Stock Exchange in France. It is located in 9, rue d'Enghien and employs 81 people.